dc.contributor
Institut Català de la Salut
dc.contributor
[Petracci E] Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy. [Pasini L, Urbini M] Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy. [Felip E] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Stella F] Thoracic Surgery Department AUSL Romagna, Forlì, Italy. [Davoli F] Thoracic Surgery Department AUSL Romagna, Ravenna, Italy
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Petracci, Elisabetta
dc.contributor.author
Pasini, Luigi
dc.contributor.author
Urbini, Milena
dc.contributor.author
stella, franco
dc.contributor.author
Davoli, Fabio
dc.contributor.author
FELIP, ENRIQUETA
dc.date.accessioned
2025-10-25T05:39:41Z
dc.date.available
2025-10-25T05:39:41Z
dc.date.issued
2025-02-14T07:46:29Z
dc.date.issued
2025-02-14T07:46:29Z
dc.date.issued
2024-08-22
dc.identifier
Petracci E, Pasini L, Urbini M, Felip E, Stella F, Davoli F, et al. Circulating cell-free and extracellular vesicles-derived microRNA as prognostic biomarkers in patients with early-stage NSCLC: results from RESTING study. J Exp Clin Cancer Res. 2024 Aug 22;43:241.
dc.identifier
https://hdl.handle.net/11351/12595
dc.identifier
10.1186/s13046-024-03156-y
dc.identifier
001295891500001
dc.identifier.uri
http://hdl.handle.net/11351/12595
dc.description.abstract
MicroRNA; Extracellular vesicles; Prognostic biomarkers
dc.description.abstract
MicroARN; Vesículas extracelulares; Biomarcadores pronósticos
dc.description.abstract
MicroARN; Vesícules extracel·lulars; Biomarcadors pronòstics
dc.description.abstract
Background
Factors to accurately stratify patients with early-stage non-small cell lung cancer (NSCLC) in different prognostic groups are still needed. This study aims to investigate 1) the prognostic potential of circulating cell-free (CF) and extracellular vesicles (EVs)-derived microRNA (miRNAs), and 2) their added value with respect to known prognostic factors (PFs).
Methods
The RESTING study is a multicentre prospective observational cohort study on resected stage IA-IIIA patients with NSCLC. The primary end-point was disease-free survival (DFS), and the main analyses were carried out separately for CF- and EV-miRNAs. CF- and EV-miRNAs were isolated from plasma, and miRNA-specific libraries were prepared and sequenced. To reach the study aims, three statistical models were specified: one using the miRNA data only (Model 1); one using both miRNAs and known PFs (age, gender, and pathological stage) (Model 2), and one using the PFs alone (Model 3). Five-fold cross-validation (CV) was used to assess the predictive performance of each. Standard Cox regression and elastic net regularized Cox regression were used.
Results
A total of 222 patients were enrolled. The median follow-up time was 26.3 (95% CI 25.4–27.6) months. From Model 1, three CF-miRNAs and 21 EV-miRNAs were associated with DFS. In Model 2, two CF-miRNAs (miR-29c-3p and miR-877-3p) and five EV-miRNAs (miR-181a-2-3p, miR-182-5p, miR-192-5p, miR-532-3p and miR-589-5p) remained associated with DFS. From pathway enrichment analysis, TGF-beta and NOTCH were the most involved pathways.
Conclusion
This study identified promising prognostic CF- and EV-miRNAs that could be used as a non-invasive, cost-effective tool to aid clinical decision-making. However, further evaluation of the obtained miRNAs in an external cohort of patients is warranted.
dc.description.abstract
This work was supported by an Italian Ministry of Health within the ERA-NET TRANSCAN-2 (JTC 2016)-RESTING project (ERP-2016-23671110).
dc.format
application/pdf
dc.relation
Journal of Experimental & Clinical Cancer Research;43
dc.relation
https://doi.org/10.1186/s13046-024-03156-y
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Pulmons - Càncer
dc.subject
Marcadors tumorals
dc.subject
CHEMICALS AND DRUGS::Nucleic Acids, Nucleotides, and Nucleosides::Antisense Elements (Genetics)::RNA, Antisense::MicroRNAs
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung
dc.subject
ANATOMY::Cells::Cellular Structures::Extracellular Space::Extracellular Vesicles
dc.subject
CHEMICALS AND DRUGS::Biological Factors::Biomarkers::Biomarkers, Tumor
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis
dc.subject
CHEMICALS AND DRUGS::Nucleic Acids, Nucleotides, and Nucleosides::Antisense Elements (Genetics)::RNA, Antisense::MicroRNAs::Circulating MicroRNA
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::nucleótidos y nucleósidos de ácidos nucleicos::elementos antisentido (genética)::ARN antiparalelo::microARN
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas
dc.subject
ANATOMÍA::células::estructuras celulares::espacio extracelular::vesículas extracelulares
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores::marcadores tumorales
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::nucleótidos y nucleósidos de ácidos nucleicos::elementos antisentido (genética)::ARN antiparalelo::microARN::microARN circulante
dc.title
Circulating cell-free and extracellular vesicles-derived microRNA as prognostic biomarkers in patients with early-stage NSCLC: results from RESTING study
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
